Retroscreen Virology Group PLC New Ordinary Shares (4572G)
04 Mars 2015 - 8:00AM
UK Regulatory
TIDMRVG
RNS Number : 4572G
Retroscreen Virology Group PLC
04 March 2015
For immediate release 07.00: 4 March 2015
RETROSCREEN VIROLOGY GROUP PLC
("Retroscreen" or the "Company")
ISSUE OF ORDINARY SHARES
The Company has issued 438,072 ordinary shares of 5p each
("Ordinary Shares" or the "Issue"), in relation to deferred
consideration for the acquisition of Activiomics Limited (233,187
ordinary shares) and an exercise of warrants by Numis Securities
Limited (204,885 ordinary shares). Following the Issue, there are
no shares outstanding relating to the deferred consideration of
Activiomics Limited and no warrants outstanding exercisable by
Numis Securities Limited.
Application has been made for the Ordinary Shares to be admitted
to AIM, with trading expected to commence on 9 March 2015
("Admission"). Upon Admission, the shares will rank pari passu in
all respects with the existing Ordinary Shares of the Company.
As a result of the Issue, the total number of ordinary shares in
issue is 68,097,515, which is the number which may be used by
shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interests in, the Company under the Financial
Conduct Authority's Disclosure and Transparency Rules.
For further information please contact:
Retroscreen Virology Group plc +44 207 756 1300
Kym Denny (CEO)
Graham Yeatman (FD)
Media Enquiries +44 203 021 3933 / +44 7854 979 420
Colin Paterson (Director of Marketing, Communication and Public
Relations)
Numis Securities Limited +44 207 260 1000
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)
Notes to Editors:
Retroscreen Virology Group plc ("Retroscreen") is a rapidly
growing life sciences company based in the UK pioneering a
technology platform called hVIVO which uses human models of disease
involving healthy volunteers to discover and study new drugs and
diagnostics. To date, Retroscreen has conducted over 35 clinical
studies, involving more than 1800 volunteers for a range of leading
industry, governmental and academic clients.
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOEEAPDDESNSEFF
Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024